Welcome to our dedicated page for Apellis Pharmace news (Ticker: APLS), a resource for investors and traders seeking the latest updates and insights on Apellis Pharmace stock.
Apellis Pharmaceuticals, Inc. reports news on its commercial-stage biopharmaceutical business centered on complement science and C3-targeting medicines. Recurring updates cover SYFOVRE, a pegcetacoplan injection for geographic atrophy secondary to age-related macular degeneration, and EMPAVELI, pegcetacoplan for rare diseases including paroxysmal nocturnal hemoglobinuria and rare kidney indications.
Company news also includes product revenue updates, ophthalmology and nephrology data presentations, pipeline references tied to complement biology, board and governance changes, investor conference participation, collaboration matters, and corporate-status developments involving strategic transactions and related shareholder communications.
Summary not available.
Summary not available.
Summary not available.
Apellis Pharmaceuticals (Nasdaq: APLS) announced a conference call and webcast to discuss its first quarter 2023 financial results scheduled for May 4, 2023, at 4:30 p.m. ET. Interested participants must pre-register for the call. The event will be accessible via the company’s website, where a replay will be available for 30 days post-event. As a leader in complement medicine, Apellis focuses on innovative therapies for serious diseases, including geographic atrophy, a major cause of blindness. With a strong pipeline of nearly a dozen clinical and pre-clinical programs, the company is committed to maximizing the potential of targeting C3. For further details, visit their official website.
Apellis Pharmaceuticals (APLS) announced positive results from the Phase 3 OAKS and DERBY studies for SYFOVRE™ (pegcetacoplan injection), the first approved treatment for geographic atrophy (GA) due to age-related macular degeneration (AMD). The analyses presented at the ARVO Annual Meeting demonstrated that SYFOVRE preserved visual function, showing a mean advantage of 5.6 letters in best corrected visual acuity compared to sham, and a 4.1-point improvement in quality-of-life scores. Additionally, SYFOVRE significantly slowed the loss of retinal cells necessary for vision, reducing photoreceptor cell loss by 46-53% and retinal pigmented epithelial cell loss by 20-27%. With marketing applications under review in multiple regions, a decision in the EU is anticipated in early 2024.
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) announced that its marketing applications for intravitreal pegcetacoplan, targeted at treating geographic atrophy (GA) secondary to age-related macular degeneration (AMD), have been validated by regulatory bodies in Canada, Australia, the UK, and Switzerland. Decisions from these authorities are anticipated in the first half of 2024. Following its first approval in the U.S., this move marks a significant step towards worldwide access to pegcetacoplan. The applications were based on Phase 3 OAKS and DERBY study results, demonstrating meaningful reductions in GA lesion growth. Additionally, a marketing authorization application is under review by the European Medicines Agency, with an expected decision in early 2024.
Apellis Pharmaceuticals has launched the GA Won’t Wait™ campaign featuring actor Henry Winkler to raise awareness about geographic atrophy (GA), a serious form of age-related macular degeneration (AMD) affecting one million Americans. The initiative aims to educate older adults on recognizing symptoms of GA and encourage them to seek timely medical advice. Winkler draws from personal experience, having witnessed the devastating effects of AMD on his father-in-law's independence. Symptoms of GA include blurred vision and difficulty with daily tasks, emphasizing the need for early diagnosis and intervention. Apellis stresses that vision loss isn't a natural part of aging, and timely eye health discussions are crucial as individuals age. For further details, visit GAwontwait.com.
Apellis Pharmaceuticals (Nasdaq: APLS) announced the approval of equity inducement awards to seven new employees on April 3, 2023. The awards, totaling 16,115 restricted stock units (RSUs), are designed to incentivize new hires as part of their employment acceptance. The RSUs will vest in increments of 25% annually over four years, contingent upon continued employment. This move aligns with Nasdaq Listing Rule 5635(c)(4) and reflects the company's strategy to attract talent in the biopharmaceutical sector, particularly in complement medicine.
As a leader in this field, Apellis aims to innovate therapies for rare and neurological diseases. The company is committed to developing transformative medicines and enhancing its workforce to support ongoing research and development efforts.
Apellis Pharmaceuticals (Nasdaq: APLS) announced on March 6, 2023, the approval of equity awards for six new employees, granted on March 1, 2023. The awards, consisting of 19,495 restricted stock units (RSUs), are part of the 2022 Inducement Stock Incentive Plan and were essential for the employees’ acceptance of their positions. Each RSU will vest in increments of 25% annually, contingent on continuous employment. This move aligns with Nasdaq Listing Rule 5635(c)(4) and showcases Apellis’ commitment to attracting talent for advancing its work in complement medicine.
Apellis Pharmaceuticals, a leader in complement medicine, announced its participation in two upcoming March investor conferences:
- Cowen 43rd Annual Healthcare Conference: Fireside chat on March 8, 2023, at 9:10 a.m. ET.
- Oppenheimer’s 33rd Annual Healthcare Conference: Virtual fireside chat on March 13, 2023, at 3:20 p.m. ET.
Both events will have live webcasts available on the company’s website, with replays accessible for 90 days. Apellis focuses on innovative therapies aimed at complex diseases, boasting two approved medications for targeting complement C3. For more details, visit apellis.com.